晚期非小细胞肺癌一线和维持治疗的选择_培训课件.ppt

IHC, immunohistochemistry. * IDST, interactive decision support tool. * Carbo, carboplatinum; cis, cisplatinum; CT, chemotherapy; doc, docetaxel; EGFR, epidermal growth factor receptor; gem, gemcitabine; OS, overall survival; pem, pemetrexed; PFS, progression-free survival; plt, platinum; TKI, tyrosine kinase inhibitor. * EGFR, epidermal growth factor receptor; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. * ALK, anaplastic lymphoma kinase; NR, not reported; NSCLC, non-small-cell lung cancer; PFS, progression-free survival. * ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; PFS, progression-free survival; RR, response rate; TRD, treatment-related death. * ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor. * OS, overall survival. * Adeno, adenocarcinoma; LCC-NOS, large-cell carcinoma, not otherwise specified; SCC, squamous cell carcinoma. * LCC-NOS, large-cell carcinoma, not otherwise specified; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma. * * * * IHC, immunohistochemistry; NOS, not otherwise specified; NSCLC, non-small-cell lung cancer. * 8832 Post-IASLC Program * C/G, cisplatin/gemcitabine; C/P, cisplatin/pemetrexed; NSCLC, non-small-cell lung cancer; OS, overall survival. ? * Cis, cisplatin; Doc, docetaxel; Gem, gemcitabine; NSCLC, non-small-cell lung cancer; OS, overall survival; Pem, pemetrexed. AC, adenocarcinoma; ERCC1, excision repair cross-complementing 1; NSCLC, non-small cell lung cancer; RRM1, ribonucleotide reductase M1; SCCA, squamous cell carcinoma; TS, thymidylate synthase. * EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; IV, intravenously; NSCLC, non-small-cell lung cancer; PDGFR, platelet-derived growth factor receptor; PO, orally; VEGF, vascular endothelial growth factor; VGFR, vascular endothelial growth factor receptor. * Bev, bevacizumab; Carbo, carboplatin; CI, confidence interval; CP, carboplatin; HR, hazard